Double-Stranded RNA Dependent Protein Kinase Derived Peptides To Promote Proliferation Of Cells And Tissues In A Controlled Manner
Description of Invention:
These applications describe a number of peptides having a minimum size of eight (8) amino acids which act as antagonists of PKR (Protein Kinase R). PKR is a critical enzyme in the interferon signaling pathway which has been implicated in cross-talk between the interferon signaling pathway and the TNF-alpha apoptosis signaling pathway. The peptide antagonists described herein may be used to inhibit apoptosis or to stimulate cell proliferation under conditions of cell cycle arrest, reduced growth or quiescence leading to possible applications in wound healing, cell culture, or skin grafts.
A portion of this work has appeared in Virology 222 (1): 193-200 (August 1 1996).
Inventors:
Donald P. Bottaro (NCI) et al.
Patent Status:
DHHS Reference No. E-137-1996/0 --
U.S. Patent 6,326,466 issued 04 Dec 2001
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics-Biological Response Modifiers-Growth Factors Cancer -Therapeutics Internal Medicine-Therapeutics Internal Medicine-Other
For Additional Information Please Contact: Susan S. Rucker J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4478
Email: ruckersu@mail.nih.gov
Fax: (301) 402-0220
